Acute Kidney Injury Market Size in the 7MM was ~USD 6,230 million in 2022, estimated DelveInsight

DelveInsight's "Acute Kidney Injury Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Acute Kidney Injury, historical and forecasted epidemiology as well as the Acute Kidney Injury market trends in the United States, EU4 (Germany, Spain, Italy, France) and the United Kingdom, and Japan.

Discover Key Insights into the Acute Kidney Injury Market with DelveInsight's In-Depth Report @ Acute Kidney Injury Market Size- https://www.delveinsight.com/sample-request/acute-kidney-injury-aki-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Acute Kidney Injury Market Research Report
• In November 2024:- Arch Biopartners Inc.- This study is a randomized, double-blind, multicenter interventional study to assess safety and efficacy of LSALT peptide versus placebo (matching drug-free saline) in patients undergoing on-pump cardiac surgery. Patients will be followed for safety and efficacy up to Day 28 (EOS), with Day 1 being the day of randomization of study drug administered at least 1 hour prior to induction of anesthesia.
• In November 2024:- Kelifarma- Phase 1B/2 Clinical Trial Assessing the Safety, Tolerability and Preliminary Efficacy of the Allogeneic Placental Mesenchymal Cells for the Preemptive Treatment of Patients At Risk for Acute Kidney Injury Following Cardiac Surgery. This clinical trial is designed to evaluate KELI-101 versus placebo for the prevention of acute kidney disease leading to chronic kidney disease in subjects at high risk for acute kidney injury following cardiac surgery. Half of the participants will receive KELI-101, while the other half will receive a placebo.
• As per DelveInsight analysis, the Acute Kidney Injury market is anticipated to witness growth at a considerable CAGR.
• The total Mortality-adjusted Incident Cases of Acute Kidney Injury in the 7MM comprised 14.6 million cases in 2022 and are projected to increase during the forecast period.
• The total Mortality-adjusted Incident Cases of Acute Kidney Injury in the United States were approximately 5.7 in 2022.
• The leading Acute Kidney Injury Companies working in the market include Atox Bio, AM-Pharma Holding, Quark-Pharmaceuticals, LG Chem, Pharming Group, Angion Biomedica, Elysium Health, Sentien Biotechnologies, Pharmazz, Arch Biopartners, Guard Therapeutics, RegeneRx Biopharmaceuticals, Cerenis Therapeutics Alloksys, Vifor Pharma, and others.
• Promising Acute Kidney Injury Pipeline Therapies in the various stages of development include TIN816, SCD-F40, THR-184, ABT-719, QPI-1002, ASP1128, LSALT Peptide, and others.

Stay ahead in the Acute Kidney Injury Therapeutics Market with DelveInsight's Strategic Report @ Acute Kidney Injury Market Outlook- https://www.delveinsight.com/sample-request/acute-kidney-injury-aki-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Acute Kidney Injury Epidemiology Insights
• Total Acute Kidney Injury Incident Population in Hospitalized Patients
• Acute Kidney Injury Mortality Adjusted Incident Population
• Acute Kidney Injury Stage-specific Incident Population
• Acute Kidney Injury Age-specific Incident Population

Download the report to understand which factors are driving Acute Kidney Injury epidemiology trends @ Acute Kidney Injury Prevalence- https://www.delveinsight.com/sample-request/acute-kidney-injury-aki-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Acute Kidney Injury Emerging Drugs

• RBT-1: Renibus Therapeutics
RBT-1 by Renibus Therapeutics is an investigational drug that upregulates anti-inflammatory, antioxidant, and iron-scavenging pathways, activating a cytoprotective preconditioning response to reduce the risk of postoperative complications and improve patient outcomes following cardiothoracic surgery. The RBT-1-mediated pharmacologic preconditioning is thought to induce broad organ protection, thereby mitigating the risks of postoperative complications and improving both short- and long-term outcomes. In July 2023, Renibus Therapeutics announced that the US FDA granted Breakthrough Therapy Designation to RBT-1 for the reduction in risk of postoperative complications in patients undergoing cardiothoracic surgery and confirmed its alignment with the company's planned Phase III pivotal trial. In October 2023, Renibus Therapeutics announced that the first patient had been dosed in the pivotal Phase III PROTECT trial of RBT-1. Top-line results are expected in mid-2025. NDA filing is anticipated by early 2026.

• OCE-205: Ocelot Bio
Ocelot Bio's lead asset, OCE-205, is a therapeutic peptide with a differentiated mechanism of action that has the potential to improve outcomes for patients with complications of end-stage liver disease (ESLD). OCE-205's innovation emanates from its design as a mixed agonist-antagonist peptide selective for the vasopressin 1a (V1a) receptor with no vasopressin 2 (v2) receptor activity at drug concentrations well above those used in treating ESLD. In August 2022, Ocelot Bio announced that the US FDA granted ODD to OCE-205 for the treatment of hepatorenal syndrome. Ocelot Bio has completed the enrolment of patients in a Phase II clinical trial of OCE-205 in hepatorenal syndrome with acute kidney injury (HRS-Acute Kidney Injury).

Acute Kidney Injury Treatment Market Landscape
The Acute Kidney Injury treatment market landscape has witnessed significant advancements over the past years, with targeted therapies playing a crucial role in improving outcomes for patients. Among these targeted therapies, the emergence of Acute Kidney Injury has garnered attention in the medical community, presenting both challenges and opportunities in treatment strategies.

Get In-Depth Knowledge on Acute Kidney Injury Market Trends and Forecasts with DelveInsight @ Acute Kidney Injury Treatment Market- https://www.delveinsight.com/sample-request/acute-kidney-injury-aki-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Major Acute Kidney Injury Companies
Several Acute Kidney Injury Companies working in the market include Atox Bio, AM-Pharma Holding, Quark-Pharmaceuticals, LG Chem, Pharming Group, Angion Biomedica, Elysium Health, Sentien Biotechnologies, Pharmazz, Arch Biopartners, Guard Therapeutics, RegeneRx Biopharmaceuticals, Cerenis Therapeutics Alloksys, Vifor Pharma, and others.

Acute Kidney Injury Market Outlook
A robust pipeline with a novel mechanism of action and increasing incidence are major market drivers of the Acute Kidney Injury therapeutics market. Additionally, the Acute Kidney Injury pipeline is also expected to change the current dynamics of the market, which presently comprises biologics and molecules with new mechanisms of action. Currently, there are no targeted pharmacotherapies approved for the treatment of Acute Kidney Injury. At present, the therapeutic market size of Acute Kidney Injury is mainly dominated by the use of RRT and off-label drugs, which include various classes such as ACE inhibitors, ARBs, Diuretics, and NSAIDs.

Unlock Strategic Insights with DelveInsight's Comprehensive Acute Kidney Injury Market Report @ Acute Kidney Injury Market Drivers and Barriers- https://www.delveinsight.com/sample-request/acute-kidney-injury-aki-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Acute Kidney Injury Drugs Uptake
The drug chapter of the Acute Kidney Injury report provides a comprehensive analysis of both marketed drugs and late-stage pipeline drugs for this condition. It delves into the details of clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages, and disadvantages of each drug, as well as the latest news and press releases related to Acute Kidney Injury.

Scope of the Acute Kidney Injury Market Research Report
• Coverage- 7MM
• Study Period- 2020-2034
• Acute Kidney Injury Companies- Atox Bio, AM-Pharma Holding, Quark-Pharmaceuticals, LG Chem, Pharming Group, Angion Biomedica, Elysium Health, Sentien Biotechnologies, Pharmazz, Arch Biopartners, Guard Therapeutics, RegeneRx Biopharmaceuticals, Cerenis Therapeutics Alloksys, Vifor Pharma, and others.
• Acute Kidney Injury Pipeline Therapies- TIN816, SCD-F40, THR-184, ABT-719, QPI-1002, ASP1128, LSALT Peptide, and others.
• Acute Kidney Injury Market Dynamics: Acute Kidney Injury Market Drivers and Barriers
• Acute Kidney Injury Market Access and Reimbursement, Unmet Needs, KOL's Views, and Analyst's Views

Learn more about the FDA-approved drugs for Acute Kidney Injury @ Drugs for Acute Kidney Injury Treatment- https://www.delveinsight.com/sample-request/acute-kidney-injury-aki-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. KEY INSIGHTS
2. REPORT INTRODUCTION
3. EXECUTIVE SUMMARY
4. KEY EVENTS
5. EPIDEMIOLOGY AND MARKET FORECAST METHODOLOGY
6. ACUTE KIDNEY INJURY MARKET OVERVIEW AT A GLANCE
7. DISEASE BACKGROUND AND OVERVIEW
8. TREATMENT AND PREVENTION
9. GUIDELINES
10. EPIDEMIOLOGY AND PATIENT POPULATION
11. PATIENT JOURNEY
12. EMERGING DRUGS
13. Acute Kidney Injury: THE 7MM ANALYSIS
14. KOL VIEWS
15. UNMET NEEDS
16. SWOT ANALYSIS
17. MARKET ACCESS AND REIMBURSEMENT
18. APPENDIX
19. DELVEINSIGHT CAPABILITIES
20. DISCLAIMER

List of Top Selling Market Research Reports in 2024

carcinoid syndrome market- https://www.delveinsight.com/report-store/carcinoid-tumor-market
fabry disease market- https://www.delveinsight.com/report-store/fabry-disease-market
gene therapy in cns disorder market- https://www.delveinsight.com/report-store/gene-therapy-in-cns-disorder-market
lice infestations market- https://www.delveinsight.com/report-store/lice-infestations-market
surgical lasers market- https://www.delveinsight.com/report-store/surgical-lasers-market
transcatheter treatment market - https://www.delveinsight.com/report-store/transcatheter-aortic-valve-replacement-market
wound healing devices market- https://www.delveinsight.com/report-store/wound-healing-devices-market
intraocular lens market- https://www.delveinsight.com/blog/top-companies-in-the-intraocular-lens-market
scoliosis market - https://www.delveinsight.com/report-store/scoliosis-market
stem cell market- https://www.delveinsight.com/report-store/stem-cell-market
surgical mask & respirator market- https://www.delveinsight.com/report-store/surgical-mask-respirator-market
urea cycle disorders market- https://www.delveinsight.com/blog/urea-cycle-disorder-market
vitreoretinal surgery devices market- https://www.delveinsight.com/report-store/vitreoretinal-surgery-devices-market
diabetic wound market- https://www.delveinsight.com/report-store/diabetic-foot-ulcers-dfus-market
lymphoedema market- https://www.delveinsight.com/report-store/lymphedema-market
nk cell therapy market- https://www.delveinsight.com/report-store/nk-cell-therapy-market
pacemakers market- https://www.delveinsight.com/report-store/pacemakers-market
sglt2 inhibitors market- https://www.delveinsight.com/report-store/sglt2-inhibitors-market
urinary catheters market- https://www.delveinsight.com/report-store/urinary-catheters-market
cardiac monitoring devices market- https://www.delveinsight.com/report-store/cardiac-monitoring-devices-market
indwelling catheters market- https://www.delveinsight.com/report-store/indwelling-catheters-market
mouth neoplasms market- https://www.delveinsight.com/sample-request/mouth-neoplasms-market
somatotropin deficiency market - https://www.delveinsight.com/report-store/somatotropin-deficiency-market
meningococcal meningitis market- https://www.delveinsight.com/report-store/meningococcal-meningitis-market
seltorexant drug market- https://www.delveinsight.com/report-store/major-depressive-disorder-market
surgical energy instruments market- https://www.delveinsight.com/report-store/surgical-energy-instruments-electrosurgical-devices-market
varicose vein treatment devices market- https://www.delveinsight.com/report-store/varicose-vein-treatment-devices-market
healthcare competitive benchmarking- https://www.delveinsight.com/consulting/competitive-benchmarking-services
bone growth stimulator market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
antibody drug conjugate market - https://www.delveinsight.com/report-store/antibody-drug-conjugate-market
microscopy device market- https://www.delveinsight.com/report-store/microscopy-device-market
novel drug delivery devices market- https://www.delveinsight.com/report-store/novel-drug-delivery-devices
total knee arthroplasty market- https://www.delveinsight.com/report-store/total-knee-arthroplasty-market
skin neoplasm market- https://www.delveinsight.com/report-store/basal-cell-carcinoma-basal-cell-epithelioma-market
asperger syndrome market- https://www.delveinsight.com/report-store/autism-spectrum-disorder-asd-market
pipeline assessment services- https://www.delveinsight.com/consulting/pipeline-assessment-services
lactose intolerance market- https://www.delveinsight.com/report-store/lactose-intolerance-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.